Quick Facts

Area of Use	Therapeutic Domain
Primary Indication	Superficial wounds (cuts, scratches, abrasions)
Additional Use	Supportive treatment of lower leg ulcers (venous ulcers)

---

Therapeutic Use and Clinical Application

Pyolysin is authorized for the topical management of superficial skin injuries. Its primary application focuses on promoting the healing process for minor wounds, such as abrasions, lacerations from cuts, and skin fissures or cracks. The core benefit is the provision of a conducive environment for cutaneous regeneration following such injuries.

In addition to the immediate care of minor skin trauma, Pyolysin is also used as a supportive measure in the long-term management of specific chronic wounds, particularly lower leg ulcers (venous leg ulcers). In this context, it is applied to the affected area after appropriate cleansing, often as part of a comprehensive care regimen. The maximum recommended treatment duration is typically restricted to three weeks, and a healthcare professional should be consulted if no improvement is observed after one week of use.

Who Can and Cannot Use Pyolysin?

This section outlines the official population eligibility rules for Pyolysin Ointment as specified by regulatory authorities, strictly determining who is permitted to use the medicine and who is excluded.

---

Official Eligibility Status

The eligible population for Pyolysin includes adults and adolescents aged 12 years and older. Regulatory documents define specific groups for whom use is prohibited, restricted, or not recommended.

Population Group	Regulatory Status
Hypersensitivity	Contraindicated (Must not be used)
Children under 12 years	Not Recommended (Insufficient safety data)
Pregnancy	Not Recommended
Lactation (Breast Area)	Restricted (Must not be applied to the breast)

---

Labeled Restrictions

Contraindications include all patients with a known allergy or hypersensitivity to the active ingredients (Pyolysin culture filtrate, Zinc oxide, Salicylic acid, bacterial lysates) or to any excipients. Furthermore, the ointment is not intended for application in the eye. Use in combination with occlusive wound dressings is advised to be avoided due to a lack of documented data for such application.

Pyolysin Interactions with other medicines and products

The official regulatory profile for Pyolysin focuses on interactions relevant to its topical application, administration method, and component properties.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with other topically applied agents may lead to an official pharmacokinetic interaction. Due to the presence of Salicylic acid, the skin absorption (exposure) of those co-administered agents may be increased, an effect specifically noted in regulatory documentation.

Within the formulation itself, a pharmacodynamic interaction is documented: the action of the Salicylic acid component is officially described as being reduced by the presence of Zinc oxide.

Interaction-Related Restrictions

The regulatory label places formal constraints on simultaneous use with certain medical products and devices:

• Occlusive Use Restriction: Use with tight or occlusive wound dressings is advised against. This restriction is based on the lack of official data regarding a potential increase in systemic absorption.
• Medical Device Restriction: The ointment should not be used simultaneously with condoms. Regulatory documentation states that the ointment base may reduce the tear strength and stability of the condom material.

No systemic metabolic or transporter-mediated drug interactions are documented in the regulatory information, consistent with the product’s minimal systemic exposure. No formal interactions with food, alcohol, or herbal products are explicitly stated.

Membrane Pore Formation

Pyolysin, a cholesterol-dependent cytolysin (CDC), acts primarily by disrupting host cell membranes. It binds to cholesterol as a soluble monomer before oligomerizing on the membrane surface, forming a ring-like prepore complex. This complex undergoes a conformational change, inserting into the lipid bilayer to create a stable, transmembrane beta-barrel pore. Pore formation leads to membrane permeabilization and subsequent cell lysis.

---

Intracellular Cascade Activation

Membrane disruption promotes the efflux of potassium ions (K^+) from the intracellular space. This ion shift triggers the assembly and activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome complex, which precedes the subsequent activation of caspase-1. Caspase-1 activation causes the proteolytic cleavage of Gasdermin D (GSDMD). The cleaved GSDMD fragment inserts into the cell membrane, forming additional pores and inducing pyroptosis, a form of lytic programmed cell death. This cascade results in the release of pro-inflammatory cytokines, such as interleukin-1beta (IL-1beta).

Official Administration Guidelines

Pyolysin is authorized for use as a cream, strictly for cutaneous (topical) application on the affected skin area. The established protocol for use is defined for this preparation.

Instruction	Application Detail
Route of Administration	Topical (Application to the skin surface only).
Dosing Schedule & Amount	Apply an adequate amount in a thin layer to the affected area.
Frequency Pattern	Superficial Wounds: 2 to 3 times per day. Lower Leg Ulcers: Once daily.
Age-Group Rules	Approved for use in adolescents and adults, 12 years of age and older. Use is not permitted for children under 12 years.
Course Duration	The maximum total treatment duration must not exceed 3 weeks.

Procedural Constraints

Specific procedural constraints for administration are established. The frequency of application is determined by the usage scenario: multiple times daily for minor injuries versus a single daily application for chronic wounds. For the use in lower leg ulcers, the protocol mandates that application must occur after cleaning the damaged skin area. Furthermore, the cream is not to be combined with occlusive wound dressings, as data regarding this type of use is unavailable, and it is specified that the medicine must be protected from frost during storage. If no improvement is observed after one week of use, professional medical review is required.

Evidence for Use in Acute Superficial Wounds

Research examined Pyolysin for its use in conditions such as common, non-extensive skin injuries, including minor cuts, scratches, and abrasions. The existing research base includes data derived from the product's clinical development dossiers and older comparative studies. Studies explored short-term symptom changes and monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

Researchers primarily monitored clinical measures of wound healing, such as the timing of re-epithelialization and closure, alongside overall assessments of the local wound environment. Findings describe patterns observed in the studies related to the timing and extent of local changes following short-term application. Observed data were generally short-term, corresponding to the defined time intervals of the acute healing phase.

Evidence for Use as Supportive Treatment for Chronic Wounds

Research explored the Pyolysin combination product in conditions associated with chronic functional limitations, such as lower leg ulcers (ulcus cruris). This evidence is primarily derived from supportive observational studies, case series, and data relating to its regulatory status as an adjuvant therapy. Studies monitored changes measured during the study period, focusing on key metrics such as the reduction in the ulcer's area and assessment of the overall wound bed condition. Findings help contextualize how patients reported their experience and contribute to the broader evidence landscape for the use of Pyolysin in combination with other standard therapies.

Research Gaps and Evidence Limitations

The overall evidence quality varies across studies, and certainty remains low regarding findings from dedicated, large-scale, modern Randomized Controlled Trials (RCTs). Comparative evidence is lacking. The follow-up durations used in the majority of the studies were limited, and long-term effects are not fully established. Furthermore, studies available for review indicate that data were insufficient to support use in children under 12 years of age, meaning results apply only to the populations studied.

Common questions about Pyolysin (FAQ)

---

Q: Can Pyolysin interact with topical steroids or other skin treatments?

According to the official product information, using Pyolysin together with other topical skin treatments may increase the absorption of those other agents. This is noted because the Pyolysin formulation contains Salicylic acid, which has properties that can affect the skin's exposure to co-administered agents.

Q: Can children use Pyolysin, and are there different guidelines?

Regulatory documents authorize Pyolysin for use in adults and adolescents aged 12 years and older. It is not permitted for use in children under 12 years of age. Official guidelines indicate that the safety data for use in younger children is currently insufficient.

Q: Why is Pyolysin sometimes recommended instead of other topical preparations?

Official product categorization describes Pyolysin as a topical combination medicinal product. It is distinguished by its composition, which integrates specific biological derivatives alongside the synthetic agents Zinc oxide and Salicylic acid.

Q: What is the typical shelf life of Pyolysin once it's been opened?

Official labeling includes an 'in-use stability period' for the product. This guideline indicates that the medicine should generally be discarded six months after the first opening of the container, to maintain product stability.

Q: What is the difference between Pyolysin and a regular antiseptic cream?

Pyolysin is officially defined as a topical combination medicinal product, rather than a standard single-agent antiseptic. This categorization is due to its unique composition, which blends specific biological derivatives with synthetic agents like Zinc oxide and Salicylic acid.

Q: Is it okay to use Pyolysin for a long period of time?

Regulatory guidelines specify that the maximum total treatment duration for Pyolysin does not exceed 3 weeks. Official documents also note that the available research studies have limited follow-up, indicating that the long-term effects of use are not fully established.

Q: Does Pyolysin have any known interactions with common oral medications?

Official regulatory information states that no systemic metabolic or transporter-mediated drug interactions are documented for Pyolysin. This is consistent with the product’s nature as a topical application with minimal systemic exposure.

Q: Can Pyolysin be used on the face or sensitive areas?

Pyolysin is strictly authorized for topical application on the affected skin area. While it is applied to the skin, official labeling places an explicit restriction against application in the eye.

Q: Is it necessary to cover the treated area after applying Pyolysin?

Official instructions note that the product is not intended for combination with tight or occlusive wound dressings. This is due to a lack of official data regarding a potential increase in systemic absorption when the area is fully covered.

Q: Can Pyolysin be used by people with a history of allergic reactions?

The medicine is officially contraindicated if a person has a known allergy or hypersensitivity to the ingredients. The medicine is not for use by those who are allergic to the active components (Pyolysin culture filtrate, Zinc oxide, Salicylic acid, bacterial lysates) or to any excipients in the product.

Q: Are there any specific food or supplement interactions mentioned for Pyolysin?

Official regulatory information explicitly states that No formal interactions with food, alcohol, or herbal products are stated in the product documentation.

Q: Do studies suggest Pyolysin helps prevent secondary infections?

The product is officially classified as a Topical Antiseptic and Wound Healing Agent. Its overall therapeutic purpose is described as creating an optimized microenvironment to support the natural tissue repair and wound healing process.

Q: What does the term 'Pyolysin' itself refer to?

Pyolysin, often abbreviated as PLO, is primarily known scientifically as a cholesterol-dependent cytolysin (CDC). This is a pore-forming protein that is secreted by the bacterium Trueperella pyogenes.

Q: What information is available regarding the long-term safety profile of Pyolysin?

Research documents indicate that the available studies had limited follow-up durations. For this reason, official regulatory notes state that the long-term effects of the product are not fully established.

Q: What are some key takeaways from the research evidence on Pyolysin?

Research has examined Pyolysin for its use in acute wounds, monitoring outcomes related to the timing of re-epithelialization and closure. Evidence for chronic wounds, such as lower leg ulcers, has focused on its role as an adjuvant therapy, monitoring metrics like the reduction in the ulcer’s area.

Q: How is Pyolysin regulated by health authorities?

Official documents indicate that Pyolysin is authorized for use by the German regulatory authority, BfArM. It is also officially stated that Pyolysin is not an FDA-approved or EMA-approved medicinal product for use in humans or animals.

How to Store and Dispose of Pyolysin

Official regulatory labeling dictates strict conditions for the storage and disposal of Pyolysin ointment/cream.

Storage Requirements

Condition	Requirement
Temperature	Store the medicine below 25°C and do not freeze it.
Container	Must be kept in the original container.
Child Safety	Keep the medicine out of the sight and reach of children.

The in-use stability period requires that the product be discarded six months after the first opening of the container.

Disposal Instructions

Unused or expired Pyolysin must not be disposed of via wastewater or household waste. All disposal must follow local pharmaceutical waste regulations and should be managed through a designated take-back scheme or pharmacy.